MedTrace Logo

Study of Efficacy and Safety of AVTR101 in Sarcopenic Elderly

NCT06788236 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to primarily evaluate the efficacy of AVTR101 to placebo on physical performance in sarcopenia patients.

Participants will:

Take AVTR101 or a placebo three times daily for 12 weeks Visit the clinic once every 4 weeks for checkups and tests

Conditions

Interventions

DRUG

AVTR101

three times daily

DRUG

Placebo

three times daily

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Ajou University School of Medicine

    collaborator OTHER

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Aventi Biotechnology Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-23
Primary Completion
2024-06-14
Completion
2024-09-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06788236 on ClinicalTrials.gov